[1] 余靓平,谢小云,魏文树,等.抗深部真菌感染药物的特性及临床应用[J].中南药学,2012,10(5):380-384.
[2] 潘伟华.抗真菌药物的应用与发展[J].世界临床医药,2014,35(12):705-708.
[3] Groll AH,De Lucca AJ,Walsb TI.Emerging targets for the development of novel antifungal therapeutics[J].Trends Mierobiol,1998,6(3):117-124.
[4] 戴振国,徐文泉,董华军.抗真菌药的分类及临床应用[J].中国医刊,2007,42(2):58-61.
[5] Silveira FP,Husain S.Fungal Infections in solid organ transplantation[J].Am J Transplant,2013,13(4):162-271.
[6] Richardson MD.Changing patterns and trends in systemic fungal infections[J].J Antimicrob Chemother,2005,56(Suppl1):5-11.
[7] Xie J,Thellend A,Becker H,et al.Synthesis and evaluation of a C-glycosyl nucleoside as an inhibitor of chitin synthase[J].Carbohydr Res,2001,334(3):177-182.
[8] Kim MK,Park HS,Kim CH,et al.Inhibitory effect of nikkomycin Z on chitin synthases in Candida albicans[J].Yeast,2002,19(4):341-349.
[9] Pfefferle W,Anke H,Bross M,et al.Asperfuran,a novel antifungal metabolite from Aspergillus oryzae[J].J Antibiot,1990,43(6):648-654.
[10] Fiser A,Sali A.Modeller:generation and refinement of homology-based protein structure models[J].Method Enzymol,2003,374(374):461-491.
[11] 陈凯先,蒋华良,嵇汝运.计算机辅助药物设计——原理、方法及应用[M].上海科学技术出版社,2000:256-281.
[12] 徐筱杰,侯廷军,乔学斌等.计算机辅助药物分子设计[M].化学工业出版社,2004:325-342.
[13] Boeckmann B,Bairoch A,Apweiler R,et al.The Swiss-Prot protein knowledgebase and its supplement TrEMBL in 2003[J].NucleicAcids Res,2003,31(1):365-370.
[14] Sali A,Blundell TL.Comparative protein modelling by satisfaction of spatialrestraints[J].J Mol Biol,1993,234(3):779-815. |